Cannenta is a biotechnology company dedicated to delivering affordable and effective advanced wound care solutions, particularly targeting emerging markets across Asia, Africa, and South America. Recognizing the growing global need—especially due to the rise in diabetes-related complications—Cannenta focuses on developing treatments for chronic and hard-to-heal wounds.​

The company holds exclusive rights to a patented sugar-based angiogenesis factor that stimulates the body's production of vascular endothelial growth factor (VEGF), promoting the formation of new blood vessels essential for wound healing. This technology can be integrated into conventional wound dressings, facilitating convenient application for patients.​

Cannenta is actively preparing for clinical trials to seek regulatory approval for its therapeutic products. The company collaborates with healthcare providers and established distributors in its target markets to expand its reach and impact.​

For more information, visit their website at www.cannenta.com.